poisar

Stocks · News reference

Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Benzinga Newsdesk

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HALO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

    Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.

    HALOABOS
  4. SEC EDGAR

    8-K filing — HALOZYME THERAPEUTICS, INC. (HALO)

    Filed: 2026-08-18 AccNo: 0001159036-26-000106 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    HALO